Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme

Anthony DelleDonne†1, Naomi Kouri†1, Lael Reinstatler1, Tomoko Sahara1, Lilin Li2, Ji Zhao2, Dennis W Dickson1, Nilufer Ertekin-Taner1,2,3 and Malcolm A Leissring*1,2

Address: 1Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL 32224, USA, 2Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, 5353 Parkside Dr, Jupiter, FL 32458, USA and 3Department of Neurology, Mayo Clinic College of Medicine, 4500 San Pablo Road S, Jacksonville, FL 32224, USA

Email: Anthony DelleDonne - delledonne.anthony@mayo.edu; Naomi Kouri - kouri.naomi@mayo.edu; Lael Reinstatler - lstiegl@emory.edu; Tomoko Sahara - sahara.tomoko@mayo.edu; Lilin Li - lilly@hotmail.com; Ji Zhao - j-zhao@hotmail.com; Dennis W Dickson - dickson.dennis@mayo.edu; Nilufer Ertekin-Taner - taner.nilufer@mayo.edu; Malcolm A Leissring* - leissring@mayo.edu

* Corresponding author    †Equal contributors

Abstract

Background: Insulin-degrading enzyme (IDE) is a widely studied zinc-metalloprotease implicated in the pathogenesis of type 2 diabetes mellitus, Alzheimer disease (AD) and varicella zoster virus infection. Despite more than six decades of research on IDE, progress has been hampered by the lack of well-characterized reagents targeting this biomedically important protease. To address this important need, we generated and characterized new mouse monoclonal antibodies (mAbs) targeting natively folded human and rodent IDE.

Results: Eight monoclonal hybridoma cell lines were derived in house from mice immunized with full-length, natively folded, recombinant human IDE. The mAbs derived from these lines were shown to detect IDE selectively and sensitively by a wide range of methods. Two mAbs in particular—designated 6A1 and 6H9—proved especially selective for IDE in immunocytochemical and immunohistochemical applications. Using a variety of methods, we show that 6A1 selectively detects both human and rodent IDE, while 6H9 selectively detects human, but not rodent, IDE, with both mAbs showing essentially no cross reactivity with other proteins in these applications. Using these novel anti-IDE mAbs, we also developed sensitive and quantitative sandwich ELISAs capable of quantifying IDE levels present in human brain extracts.

Conclusion: We succeeded in developing novel mAbs that selectively detect rodent and/or human IDE, which we have shown to be suitable for a wide range of applications, including western blotting, immunoprecipitation, immunocytochemistry, immunohistochemistry, and quantitative sandwich ELISAs. These novel anti-IDE mAbs and the assays derived from them constitute important new tools for addressing many unresolved questions about the basic biology of IDE and its role in multiple highly prevalent human diseases.
Background

Insulin-degrading enzyme (IDE; EC 3.4.24.56; a.k.a. insulin, insulinase, insulin protease) is an atypical zinc-metalloprotease that hydrolyzes several biomedically important intermediate-sized peptide substrates, including insulin, insulin-like growth factor-2, glucagon, amylin, and the amyloid β-protein [1-3]. IDE is implicated in the pathogenesis of Alzheimer disease (AD) [4,5] and type-2 diabetes mellitus [6-8], and has also been identified as the cellular receptor for varicella zoster virus infection and cell-to-cell spread [9].

Despite the clear biomedical significance of this protease, many fundamental questions about the basic biology of IDE remain unresolved, due in part to a lack of sufficiently selective reagents targeting this ubiquitous protease. In particular, the precise subcellular localization of IDE remains poorly defined. Although IDE is well-established to reside in cytosol [1] and mitochondria [10], reports of IDE’s localization to other pathophysiologically important subcellular compartments—such as endosomes [11]—have not been confirmed by microscopic analysis of intact cells with well-characterized anti-IDE antibodies. Moreover, the mechanisms underlying the export of IDE from the cell are completely unknown, though it has recently been demonstrated that they involve an unconventional, non-classical secretion pathway [12]. Methods capable of detecting and quantifying secreted forms of IDE would greatly facilitate the elucidation of this important pathway. Finally, it will be important to detect genetically or environmentally induced variations in IDE protein levels, which will require the development of assays permitting accurate quantification of IDE levels in relevant tissues.

To help close these gaps in our understanding of the biology of IDE, we developed eight novel mouse mAbs that detect rodent and/or human IDE in diverse applications in a highly selective and species-specific manner. Notably, a subset of these mAbs were particularly well suited for detecting endogenous IDE by immunocytochemistry and immunohistochemistry. We also describe the development of sensitive and quantitative sandwich ELISAs capable of detecting variations in IDE levels in human brain extracts. Collectively, these novel anti-IDE mAbs, and the ELISA incorporating them, constitute important new tools for investigating both the basic biology of IDE and its potential derangement in disease.

Table 1: Properties of anti-IDE monoclonal antibodies

| Clone: | 2A1 | 3D8 | 4B4 | 4C5 | 4H5 | 4H7 | 6A1 | 6H9 |
|--------|-----|-----|-----|-----|-----|-----|-----|-----|
| Isotype: | IgG1κ | IgG1κ | IgG1κ | IgG2aκ | IgG2aκ | IgG1κ | IgG2aκ | IgG2aκ |
| ELISA half-titer (ng/mL): | 250 | 32 | 32 | 8 | 4 | 125 | 2 | 8 |

Results

Detailed methods for all experimental procedures are provided in the Additional File 1.

Generation of Monoclonal Hybridomas Expressing Anti-IDE mAbs

To generate mAbs targeting IDE, BALB/ByJ mice were immunized in house with highly purified, full-length, natively folded, recombinant human IDE. Spleen cells were harvested and fused with SP2/0-Ag14 myeloma cells, and monoclonal hybridomas were selected for by growth in HAT medium. From among a total of 576 hybridoma lines, 8 clones were selected and expanded based on their reactivity against a second, natively folded, recombinant human IDE protein. The anti-IDE mAbs derived from these hybridomas were purified by protein G-sepharose chromatography, and their isotypes and half-titers were determined (Table 1).

Western Blotting and Immunoprecipitation

By western blotting, endogenous human IDE present in HeLa cell extracts was readily detected by 4 anti-IDE mAbs: 2A1, 4H5, 6A1 and 6H9 (Fig. 1A). These mAbs each detected a prominent ~110-kDa band identical in size to that detected by the well characterized rabbit polyclonal antibody, αIDE-1 [13] (Fig. 1A). Little to no nonspecific staining was observed, which in no case exceeded that detected by identical amounts of normal mouse IgG (Fig. 1A). Rodent IDE extracted from mouse liver, by contrast, was detected by 4H5 and 6A1, but not by other mAbs (Fig. 1B). 6H9 detected multiple bands, including some near ~110 kDa (Fig. 1B); however, these bands were found to be non-specific, because an identical pattern was observed in cell extracts derived from wild-type and IDE-KO mice (not shown).

With the exception of 4H5, human IDE was successfully immunoprecipitated by all anti-IDE mAbs, albeit the efficiency of 4C5 was less than the other mAbs (Fig. 1C). By contrast, rodent IDE was successfully immunoprecipitated by only a single mAb, 6A1 (Fig. 1C).

Immunocytochemistry

To evaluate the specificity of our anti-IDE mAbs for detecting rodent IDE by immunocytochemistry, we compared the signal detected in immortalized hepatocytes derived from wild-type mice or mice lacking IDE (IDE-KO mice). From among all antibodies tested, including multiple
commercially available ones, 6A1 was unique in strongly labeling wild-type hepatocytes (Fig. 2A), while showing no immunoreactivity in IDE-KO hepatocytes imaged under identical conditions (Fig. 2B). Consistent with previous results [14], IDE was found to be widely distributed throughout the cytoplasm and largely excluded from the nucleus by high-resolution confocal microscopy (Fig. 2A).

To evaluate the specificity of our mAbs for detecting human but not rodent IDE by immunocytochemistry, we analyzed Chinese hamster ovary (CHO) cells transiently transfected with a vector encoding human IDE. Among the antibodies tested, superior results were obtained with 6H9, which was found to intensely stain cells expressing human IDE, while showing no background staining in neighboring, nontransfected cells expressing rodent IDE (Fig. 1C). These results are consistent with the western blotting and immunoprecipitation results obtained for this mAb (Fig 1). 6H9 also readily detected endogenous levels of human IDE, as revealed by prominent staining present in unmodified HeLa cells (Fig. 1D).

**Immunofluorescence and Immunohistochemistry**

The suitability of the anti-IDE mAbs for immunohistochemical applications was assessed by staining paraffin-embedded sections from pathologically unaffected human hippocampus and cerebellum. 6H9 (Fig. 3) and 6A1 (not shown) showed highly similar patterns of staining relative to one another as determined by both immunofluorescent (Fig. 3A, C) and immunohistochemical (Fig. 3B, C) methods. As expected from the ubiquitous expression of IDE, immunoreactivity was broadly distributed, though some cell-type specific variations in staining intensity were apparent. Notably, a subset of neuronal cells showed comparatively higher IDE immunoreactivity, including CA1 pyramidal cells in the hippocampus (Fig. 3A, B) and Purkinje cells in the cerebellum (Fig. 3C, D).

**IDE Sandwich ELISAs**

We next sought to develop a sandwich ELISA capable of detecting and quantifying IDE present in human brain extracts. From among several configurations tested, we elected to characterize a sandwich ELISA using 6H9 for capture and horse radish peroxidase (HRP)-conjugated 6A1 for detection, as these two antibodies had the most robust combined results with the western blot, immunofluorescent and immunohistochemical assays. This ELISA showed a linear response to a wide range of concentrations of recombinant IDE, where the minimum amount of recombinant IDE that was repeatedly and reliably detected was 1.7 ng/well, or 156 pM in 100 μL (Fig. 4A).

To validate the ability of this ELISA to detect variations in IDE levels from human brain samples, we quantified IDE levels in cerebellar extracts from a large set of autopsied AD brains both by western blot analysis with 2A1 (see Fig. 4B) and by 6H9/6A1 sandwich ELISA. For both methods, absolute IDE levels were determined by calibration to internal recombinant human IDE standards. After appropriate quality control measures and normalization to internal control samples (see Additional File 1), IDE levels within a total of 49 human cerebellar samples were successfully measured by both methodologies (Fig. 4C).
Despite the different set of antibodies employed and potential batch effects, we observed a highly significant correlation between results obtained with the two methodologies (p < 0.0001, r² = 0.3). Overall, the 6H9/6A1 ELISA consistently detected less IDE protein (7 ± 1%, mean ± SD) relative to that detected by western blotting (see Discussion). Using a subset of brain samples as a reference, qualitatively and quantitatively similar results were also obtained using ELISAs configured with multiple different anti-IDE mAbs combinations (not shown).

**Discussion**

In the present study, we succeeded in developing 8 monoclonal hybridoma lines in house that express a versatile set of anti-IDE mAbs. Two mAbs in particular—6A1 and 6H9—were found to be useful in a wide array of applications, detecting human and rodent IDE in a highly selective and species-specific manner. 6A1 was found to detect both human and rodent IDE by western blotting, immunoprecipitation, immunocytochemistry, and immunohistochemistry. 6H9, by contrast, detected human but not rodent IDE, as determined by the same methods.

We also developed sandwich ELISAs capable of detecting human IDE in brain extracts and validated the ELISA results with quantitative western blot analysis. There was a significant correlation between IDE levels detected by western blotting with 2A1 and with the 6H9/6A1 sandwich ELISA. Despite the strong correlation between the two methods, the absolute amounts of IDE detected by ELISA were consistently lower than those detected by western blotting. This disparity may be attributable technical considerations, such as the particular protein extraction conditions used in this study (see Additional File 1), which could have denatured IDE sufficiently to affect its detection by ELISA. Future studies comparing the outcome obtained under different extraction conditions should resolve this question. On the other hand, several intriguing biological explanations also exist. For example, endogenous IDE might normally be complexed to other proteins, or may contain post-translational modifications, either or both of which could sterically block or remove the epitopes recognized by the antibodies used for ELISAs. Alternatively, or in addition, it may be that a substantial portion of IDE present in post-mortem extracts is itself not natively folded or is modified in other ways.

Although outside the scope of this methodology paper, it is notable that there was substantial variation in absolute variation in...
IDE levels (~10-fold) detected by both ELISA and Western blotting in the large set of AD cerebellar samples we examined. In the future, it will be important to evaluate whether these changes correlate with genetic or other risk factors for AD. Further insight into these and many other important questions will be facilitated by the development of this well-characterized and versatile set of anti-IDE mAbs.

Abbreviations

AD: Alzheimer disease; ELISA: enzyme-linked immunosorbent assay; HAT: hypoxanthine, aminopterin, and thymidine; HRP: horse radish peroxidase; IDE: insulin-degrading enzyme; IDE-KO: insulin-degrading enzyme knockout; mAb: monoclonal antibody.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

AD conducted immunohistochemical and immunofluorescent staining, assisted with microscopy and wrote the manuscript. NK conducted western blot analyses and ELISAs on human brain extracts. LR participated in fluorescence microscopy, generated HRP-conjugated IDE mAbs, and tested and optimized IDE ELISAs. JZ conducted fluorescence confocal microscopy. LL prepared and purified recombinant IDE proteins, immunized mice, harvested B cells, generated hybridomas, tested hybridoma clones for IDE immunoreactivity in various formats, expanded and isotyped selected clones, generated immortalized murine hepatocyte cell lines, and tested mAbs by western blotting and immunoprecipitation. TS conducted immunocytochemistry on transiently transfected CHO cells. DWD aided in antibody analysis and characterization on human tissue samples. NET designed experiments, analyzed data and wrote the manuscript. MAL designed experiments, participated in fluorescence microscopy, analyzed data and wrote the manuscript.

Acknowledgements

The authors thank Dennis Selkoe (Harvard Medical School) for the αIDE-1 antibody and Ms. Qun Lu and Christelle Cabrol for superb technical assistance. Supported by National Institutes of Health Grants AG025070 and DA024888 to MAL and CTSA KL2 RR024151 award to NET. We thank the patients and their families for their participation in our research studies. We gratefully acknowledge the Mayo Clinic Alzheimer’s Disease Research Center for its support.

References

1. Duckworth WC, Bennett RG, Hamel FG: Insulin degradation: progress and potential. Endocr Rev 1998, 19:608-624.
2. Hersh LB: The insulysin (insulin degrading enzyme) enigma. Cell Mol Life Sci 2006, 63:2432-2434.
3. Malito E, Hulse RE, Tang WJ: Amyloid beta-degrading cryptidases: insulin degrading enzyme, prionsequence peptidase, and neprilysins. Cell Mol Life Sci 2008, 65:2574-2585.
4. Selkoe DJ: Clearing the brain’s amyloid cobwebs. Neuron 2001, 32:177-180.
5. Leissring MA: The AβCs of Aβ-cleaving proteases. J Biol Chem 2008, 283:29645-29649.
6. Fakhril-Rad H, Nikoshkov A, Kamel A, Fernstrom M, Zierath JR, Norgren S, Luthman H, Gall J: Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum Mol Genet 2000, 9:2149-2158.
7. Karamohamed S, Demissie S, Volcjak J, Liu C, Heard-Costa N, Liu J, Shoemaker CM, Panhuysen CI, Meigs JB, Wilson P, et al.: Polymorphisms in the insulin-degrading enzyme gene are associated...
with type 2 diabetes in men from the NHLBI Framingham Heart Study. Diabetes 2003, 52:1562-1567.

8. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ: Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 2004, 164:1425-1434.

9. Li Q, Ali MA, Cohen J: Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell 2006, 127:305-316.

10. Leissring MA, Farris W, Wu X, Christodoulou DC, Haigis MC, Guarente L, Selkoe DJ: Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J 2004, 383:439-446.

11. Authier F, Cameron PH, Merlen C, Kousch M, Briand G: Endosomal proteolysis of glucagon at neutral pH generates a bioactive degradation product miniglucagon-(19-29). Endocrinology 2003, 144:3535-3536.

12. Zhao J, Li L, Leissring MA: Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Mol Neurodegener 2009, 4:4.

13. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ: Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000, 20:1657-1665.

14. Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ: Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry 2005, 44:6513-6525.